– Preorders can be made by visiting www.tomeskincare.com –

– Dermata is ready to begin shipping orders on the expected launch date of August 25, 2026 –

– Tome Foundational Treatment is a once-weekly topical mask for skin renewal –

SAN DIEGO, CA / ACCESS Newswire / August 21, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) (“Dermata” or the “Company”), a science-driven leader in dermatologic solutions, today announced that Tome Foundational Treatment, the Company’s first direct-to-consumer skincare product, is now open to preorders. The Tome Foundational Treatment is expected to start shipping on August 25, 2026.

Beginning today, customers can preorder Tome Foundational Treatment at www.tomeskincare.com. The Foundational Treatment will retail for $178 (about $45/treatment) with subscribers receiving a 10% discount. Customers will receive four once-weekly treatments of the Foundational Treatment with each once-weekly treatment including a cup of the Company’s Bioneedle™ powder, a tube of Activator, and an application brush. Right before use, the consumer mixes the product then applies it as a mask, ensuring even distribution to achieve maximum potency of the Bioneedle. The Foundational Treatment is a novel skin reset that represents the Company’s first product in a planned portfolio of consumer skincare products to be developed under the Tome brand.

“Opening preorders is an exciting milestone for us as we move closer to getting Tome Foundational Treatment into the hands of customers,” commented Gerry Proehl, Chief Executive Officer of Dermata. “Over the past year, our team has been focused on preparing for commercialization, including building the Tome brand, researching consumers skincare wants, ordering supplies, designing packaging, optimizing the supply chain, and building a social media presence. With preorders now underway, we are entering the final stage ahead of our planned commercial launch, expected on August 25, 2026,” continued Mr. Proehl. “We believe that our Foundational Treatment can fill the “white-space” in the current skincare market by providing consumers with a natural, topical product that is safe to use at home, but provides professional-grade results,” concluded Mr. Proehl.

About Tome

Tome is a skincare brand forging a timeless ingredient with modern science to create professional-grade skincare powered by natural and safe ingredients. Built around Bioneedle™, Tome’s signature ingredient made from exclusively sourced, wild harvested Spongilla lacustris, a freshwater sponge, Tome’s once-weekly Foundational Treatment brings a powerful skin resurfacing treatment into the home. To learn more, visit www.tomeskincare.com

About Dermata

Dermata Therapeutics is a science-driven dermatology company focused on developing innovative skincare solutions that are backed by science and research. Through its consumer brand, Tome, Dermata is expanding its platform to deliver clinically tested skincare products directly to consumers. Dermata is headquartered in San Diego, California. For more information, visit www.dermatarx.com.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and new risks may emerge from time to time. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but are not limited to, statements related to: Dermata’s shift to commercialize skincare products; the timing of any future announcements; the anticipated benefits of Dermata’s strategic shift, including acceleration of its path to commercialization, reduction of regulatory burdens, and expansion into broader consumer markets; the expected timing and success of any planned product launches; the potential market acceptance of any products; and other factors described in the Company’s filings with the Securities and Exchange Commission. These forward-looking statements are generally identified by the use of such words as “may,” “could,” “should,” “would,” “believe,” “anticipate,” “forecast,” “estimate,” “expect,” “intend,” “plan,” “continue,” “outlook,” “will,” “potential” and similar statements of a future or forward-looking nature. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in product development and commercialization. For a discussion of these and other factors, please refer to Dermata’s filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Dermata undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof, except as required by law.

Dermata Investors:

Cliff Mastricola
Investor Relations
cmastricola@dermatarx.com

SOURCE: Dermata Therapeutics

View the original press release on ACCESS Newswire

Media gallery

About The Author
Dermata Therapeutics